We’ve written about states’ “right to try” laws, which expand desperate patients’ power to use drugs before the FDA approves them. These laws, gaining bipartisan approval in a growing number of states, open up the question of whether FDA powers that limit the availability of new medicines can be challenged by states.
A couple of pharmaceutical executives have written a very honest article about their experience dealing with a request for compassionate use of an experimental drug, while one of them was CEO of the company that was developing it.
Read he entire column at NCPA's Health Policy Blog.
Research and commentary from a former senior executive in the U.S. Department of Health & Human Services
No comments:
Post a Comment